Feasibility and efficacy of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma after sorafenib by Terashima Takeshi et al.
Feasibility and efficacy of hepatic arterial
infusion chemotherapy for advanced
hepatocellular carcinoma after sorafenib
著者 Terashima Takeshi, Yamashita Tatsuya, Arai
Kuniaki, Sunagozaka Hajime, Kitahara Masaaki,
Nakagawa Hidetoshi, Kagaya Takashi, Mizukoshi










Feasibility and efficacy of hepatic arterial infusion chemotherapy for advanced 
hepatocellular carcinoma after sorafenib 
 
Authors: Takeshi Terashima1, Tatsuya Yamashita1, Kuniaki Arai1, Hajime Sunagozaka1, 
Masaaki Kitahara1, Hidetoshi Nakagawa1, Takashi Kagaya1, Eishiro Mizukoshi1, Masao Honda1, 
Shuichi Kaneko1 
 
Affiliation: 1 Department of Gastroenterology, Kanazawa University Hospital, Kanazawa, 
Ishikawa 920-8641, Japan 
 
Corresponding author: Shuichi Kaneko, M.D., Ph.D. 










Aim: Sorafenib is the standard treatment for advanced hepatocellular carcinoma (HCC). 
However, although there is no proven therapeutic procedure following the termination of 
sorafenib, hepatic arterial infusion chemotherapy (HAIC) may be a treatment option in 
advanced HCC. The aim of this study was to evaluate feasibility and efficacy of HAIC for 
patients with advanced HCC as subsequent therapy. 
Methods: We retrospectively evaluated 27 consecutive patients with advanced HCC who were 
treated with HAIC following sorafenib between June 2009 and December 2012 at our hospital. 
Cisplatin (20 mg/m2/day) was administered via the hepatic artery for 10 min, prior to the 
continuous administration of 5-FU (330 mg/m2/day) over 24 h from days 1–5 and 8–12 and the 
subcutaneous administration of pegylated interferon α-2b (1 μg/kg) on days 1, 8, 15, and 22. A 
treatment cycle consisted of 28 days of drug administration followed by 14 days of rest. 
Results: The toxicity profile showed that hematological toxicities were common, and grade 3/4 
neutropenia and thrombocytopenia were observed (51.9% and 48.1%, respectively). Five 
patients (18.5%) experienced device-related complications. No unexpected adverse reactions 
and no treatment-related deaths were observed. Partial response was obtained in eight patients 
(29.6%), and stable disease was noted in nine patients (33.3%). Median progression-free 
survival and median survival time from initiation of HAIC were 4.0 and 7.6 months, 
respectively. 
Conclusions: Because HAIC was well tolerated and exhibited moderate antitumor activity, it is 
a potentially useful treatment procedure in patients with advanced HCC even after failure of 
sorafenib. 
 





 Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third leading cause 
of cancer-related mortality worldwide 1. A variety of new techniques of imaging modalities have 
enabled the detection of HCC at an early stage 2, and advances in various therapeutic procedures 
have improved its curability 3,4. However, the number of patients with HCC who can be treated 
curatively is limited because of impaired hepatic function and frequent recurrence even after 
curative therapy. The prognosis of patients with advanced HCC where tumor has spread over 
the liver or invaded major vessels remains extremely poor 5. 
 Sorafenib, an oral multikinase inhibitor that blocks tumor cell proliferation and angiogenesis, 
is the only systemic therapy that has shown survival benefit for patients with advanced HCC 6.7, 
and it is recognized worldwide as standard first-line therapy in advanced HCC 8.9. Alternative 
systemic chemotherapies using cytotoxic agents or novel targeted drugs have been attempted in 
patients with advanced HCC 10,11; however, to date none have proven effective, except sorafenib. 
Moreover, following sorafenib therapy most patients are not suitable candidates for subsequent 
therapy because of the progressive nature of their disease, poor general condition, and impaired 
hepatic function. 
 Compared with systemic chemotherapy, hepatic arterial infusion chemotherapy (HAIC) is 
based on theoretical advantages such as higher concentrations of drugs delivered directly to 
tumors 12 and first-pass effect reducing systemic toxicity 13. Although few reports have recorded 
the survival benefits of HAIC, HAIC in combination with interferon (IFN) has been reported to 
be a useful treatment procedure in patients with advanced HCC 14,15. Although an optimal 
protocol of HAIC has not been established, the clinical benefits of HAIC regimen consisting of 
5-FU and cisplatin with IFN were reported in a randomized phase II study 15. However it 
remains unclear whether HAIC is also safe and effective in patients with advanced HCC who 
were previously administered sorafenib. 
 The aim of the present study was to evaluate the feasibility and efficacy of HAIC in patients 
with advanced HCC after failure of sorafenib therapy. This approach provides useful 





 All of 68 consecutive patients with unresectable advanced HCC who had received sorafenib 
monotherapy at Kanazawa University Hospital and for whom this therapy was subsequently 
stopped because of tumor progression or/and unacceptable adverse effects between June 2009 
and December 2012 were considered for enrollment. HCC was diagnosed by either histological 
confirmation or typical radiological findings, which showed hyperattenuation in the early phase 
and hypoattenuation in the late phase on dynamic computed tomography (CT) 16. All patients 
underwent dynamic CT to assess the extent of the cancer, and their hepatic and major organ 
functions were evaluated by physical examination and laboratory findings. We reviewed 
patients’ medical records and investigated their backgrounds, treatment courses, and outcomes. 
 
Sorafenib 
The following were the inclusion criteria for sorafenib at our institution: patients with 
advanced HCC involving macroscopic vascular invasion, extrahepatic lesions, and/or 
intrahepatic multiple lesions considered unsuitable for surgical resection, locoregional therapy, 
or transarterial chemoembolization; all patients with an Eastern Cooperative Oncology Group 
(ECOG) performance status score of ≤2 and with appropriate function of major organs, such as 
bone marrow, kidney, and heart; and patients categorized as Child–Pugh A in terms of hepatic 
function. 
 HAIC 
 The inclusion criteria for HAIC at our institution is nearly same as that of sorafenib. Patients 
with extrahepatic lesions were also considered eligible if these lesions were mild, and 
intrahepatic lesions were considered as prognostic factors. With regard to hepatic function, 
patients categorized as Child–Pugh A or B were eligible. 
 The reservoir system implantation technique was the same as described previously 15. 
Catheters were introduced through the right femoral artery, and angiography from the celiac 
artery was initially performed to localize the HCC and evaluate intra- and extrahepatic 
vascularization. We then inserted a catheter with a side vent into the gastroduodenal artery, 
positioning the vent in the common hepatic artery using an image-guided procedure. The 
gastroduodenal artery, right gastric artery, and other arteries presumed to supply the 
gastroduodenal region were embolized as far as possible to prevent gastrointestinal mucositis. 
The other end of the catheter was connected to an injection port that was subcutaneously 
implanted in the right lower abdomen. Finally, blood flow redistribution was confirmed. 
 HAIC was initiated approximately 5 days after implantation of the reservoir, and the following 
protocol was then implemented: 5-FU (330 mg/m2/day) was continuously administered via the 
hepatic artery using an infuser pump over 24 h from days 1–5 and 8–12, and cisplatin (20 
mg/m2/day) was also administered via the hepatic artery for 10 min prior to 5-FU administration. 
Pegylated interferon α-2b (1.0 μg/kg) was subcutaneously administered on days 1, 8, 15, and 22. 
A treatment cycle consisted of 28 days of drug administration followed by 14 days’ rest. The 
treatment protocol was approved by the Ethics Committee of Kanazawa University, and 
informed consent for participation in the study was obtained from each subject. The study 
conformed to the guidelines of the 1975 Declaration of Helsinki. 
 
Evaluation 
 Tumor staging was assessed according to the criteria of the Liver Cancer Study Group of Japan 
17,18. The efficacies of HAIC and sorafenib were assessed every 4–6 weeks by dynamic CT, and 
response to chemotherapy was assessed according to the Response Evaluation Criteria in Solid 
Tumors ver. 1.1 19. Response rate was defined as the sum of complete and partial response rates. 
Similar to an approach adopted in a recent report, the causes of progression after sorafenib 
therapy (progression pattern) were classified as follows: intra-hepatic growth (IHG), 
extra-hepatic growth (EHG), new intra-hepatic lesion (NIH), or new extra-hepatic lesion and/or 
vascular invasion (NEH) 20. Adverse effects, including both hematological and 




 Progression-free survival (PFS) was calculated from the first day of HAIC until either the date 
of radiological progression, the date of death, or the last day of the follow-up period. Overall 
survival (OS) was calculated from the first day of HAIC until either the date of death or the last 
day of the follow-up period. A chi-squared test was used to analyze the predictive factor for the 
response to HAIC. To compare prognosis according to response to chemotherapy and the 
progression pattern, cumulative survival was calculated using the Kaplan–Meier method 21 and 
any differences were evaluated using the log-rank test. P-values of <0.05 were considered to be 
statistically significant, and all tests were two-sided. All statistical analyses were performed 






 Of 68 patients, 41 were not treated with HAIC because of either poor general condition (n = 
12), massive extrahepatic lesions (n = 9), inadequate major organ function (n = 8), treatment 
with HAIC prior to sorafenib therapy (n = 7), or refusal to be treated with HAIC (n = 5). Finally, 
27 patients who had been treated with HAIC were analyzed in this study, all of whom had 
previously received sorafenib monotherapy. The response and tumor control rates for sorafenib 
therapy were 7.4% and 44.4%, respectively. In 22 patients (81.5%), sorafenib therapy was 
terminated because of tumor progression and in 5 (18.5%) because of unacceptable adverse 
effects. The median period of sorafenib therapy was 2.4 months (range, 0.1–18.0). 
 Patient characteristics at commencement of treatment with HAIC are summarized in Table 1. 
Because hepatic function was impaired in more than half of the patients in this study, 18 patients 
(66.7%) were classified as Child–Pugh class B or C. Macroscopic vascular invasion and 
extrahepatic metastasis were observed in 25.9% and 44.4% of the patients, respectively.  
 
Treatment 
 A total of 60 courses were administered to 27 patients, with a median number of 2 (range, 0–5). 
All, but 2, patients completed at least one course of HAIC. The median duration between 
cessation of sorafenib therapy and commencement of HAIC was 1.2 months (range, 0–9.0). The 
median observation period from commencement of HAIC was 7.0 months (range, 0.8–48.0). 
Treatment with HAIC was terminated in 25 patients due to radiological tumor progression (20 
patients), symptomatic tumor progression (1 patient), or change in the treatment procedure (4 
patients); however, there were no patients in whom HAIC was terminated because of adverse 




 All 27 patients were assessed for adverse effects, and the toxicity profile of HAIC is 
summarized in Table 2. Hematological toxicities were common, particularly grade 3/4 
neutropenia and grade 3/4 thrombocytopenia, which were observed in 14 (51.9%) and 12 
(48.1%) patients, respectively, even though no serious complication such as sepsis or bleeding 
were observed and all toxicities were tolerable and reversible. Mild and low-frequency 
nonhematological toxicities were observed, except in one patient who had grade 3 diarrhea. 
Although 5 patients (18.5%) had device-related complications (3 catheter obstruction, 1 hepatic 
artery occlusion, and 1 hepatic arteritis), all issues were satisfactorily resolved by either 
exchanging the reservoir or conservative therapy. No unexpected adverse reactions were noted, 
and no treatment-related deaths were observed. 
 
Response to treatment and patient outcomes 
 Of the 27 patients, one died due to tumor progression and hepatic failure before radiological 
assessment could be performed; however, the remaining 26 were assessable for response to 
treatment. Tumor responses to HAIC are shown in Table 3. Although no patient achieved 
complete response, 8 patients (29.6%) achieved partial response (PR) and 9 (33.3%) achieved 
stable disease (SD); therefore, the response rate to HAIC was 29.6%. These results were 
independent of the Child–Pugh class, the response to previous sorafenib therapy, and the 
progression pattern (Table 3), and none of the tested factors were found to be a significant 
predictive factor for response to HAIC (Supplementary Table). 
 The median PFS of patients from commencement of HAIC was 4.0 months (Figure 1). The 
median survival time (MST) of all patients was 7.6 months, with a 1-, 2-, and 3-year survival 
rate of 29.4%, 24.5%, and 16.4%, respectively (Figure 2A). The MST of patients who achieved 
PR were 36.7 months, which was significantly better than that of patients who achieved 
SD/progressive disease /not evaluable, i.e., 6.6 months (p < 0.01; Figure 2B). Patient prognosis 




 The development of a safe and effective alternative therapy is essential because sorafenib, 
which represented a breakthrough in the treatment of advanced HCC, had a low response rate 
and frequent adverse effects, often leading to a cessation of treatment 22,23. An increasing 
number of emerging agents, including novel molecular targeted drugs, have been attempted in 
sorafenib refractory HCC. Nevertheless, their efficacy was found to be limited (response rate, 
0%–4.3%; time to progression, 1.6–2.7 months) 24-26. 
 The first aim of this study was to investigate the feasibility of HAIC in advanced HCC after 
the failure of sorafenib therapy. In this study, the frequency of hematological toxicity, 
particularly neutropenia and thrombocytopenia, was high. One of the possible causes of these 
toxicities was pre-existing pancytopenia derived from liver cirrhosis in most patients, and 
another was the concurrent administration of IFN added to 5-FU and CDDP 15. All of the 
patients recovered immediately after the end of treatment and no additional complications were 
noted. Moreover, the frequencies of leukocytopenia, neutropenia, and thrombocytopenia 
observed in this study (74.1%, 77.8%, and 88.9%, respectively) were very similar to those of 
patients who were not pretreated by sorafenib and underwent HAIC with the same protocol, 
including 5-FU/CDDP/IFN (75.4%, 77.2%, and 89.5%, respectively) 15 , which suggested that 
prior administration of sorafenib did not have an additional impact on hematological toxicities. 
With regard to nonhematological toxicities, most of them were less frequent than those in a 
previous report 15, and there were no unexpected adverse reactions. These favorable results may 
be derived from newly available drugs such as a second-generation 5-hydroxytryptamine 3 
receptor antagonist and neurokinin-1-receptor antagonist or active supportive therapy. These 
findings suggested that HAIC was considered tolerable even for those patients who were 
previously administered sorafenib.  
 The response rate obtained in the present study (29.6%) appears to be low compared with that 
of previous reports 14,15. Although it is difficult to compare the response rates among studies, 
possible reasons include variation in patients’ hepatic function, the criteria used to evaluate 
responses, the effect of previous administration of sorafenib, and the relatively small number of 
patients. In addition, the proportion of patients with extrahepatic lesions may have been a 
meaningful factor because it was higher (44.4%) in this study than that of the previous study 
(0-14%) 14,15 and the response rate was reported to be lower in patients with HCC having 
extrahepatic metastases than in those without 27. We could not identify any significant predictive 
markers for the response to HAIC in this study, and further investigation is needed to examine 
the factors affecting the response rate of HAIC, and to select the appropriate population to 
receive HAIC after sorafenib therapy. 
 Another interesting finding of the present study was that half of our patients were categorized 
as Child–Pugh class B, and no correlation was observed between the response to HAIC and 
Child–Pugh classification. Although certain molecular targeted agents are currently being tested 
for sorafenib-refractory patients with HCC, the objectives in most of these trials are restricted to 
patients with good hepatic function. Other reports have described systemic chemotherapy by 
combination of gemcitabine and oxaliplatin is potentially safe for patients with Child–Pugh 
class B 28 and useful in sorafenib-refractory patients with HCC 29. The results of the present 
study suggest that HAIC may be also considered as one of treatment procedures for patients 
with Child–Pugh class B after sorafenib therapy. 
 The present study has several limitations, including its retrospective nature, the small number 
of patients, the lack of controls, and single-institution subsets. A prospective trial with a larger 
number of patients in proper design is needed to confirm our findings. 
 In conclusion, HAIC has good feasibility and moderate antitumor activity and is a useful 
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Figure 1: Kaplan–Meier plot of PFS since commencement of hepatic arterial infusion 
chemotherapy (HAIC). Median PFS was 4.0 months 
 
Figure 2: Kaplan–Meier plot of overall survival since commencement of HAIC: (A) all patients 
and (B) according to response to HAIC. The median survival time (MST) of all patients was 7.6 
months, and the MST of patients who achieved partial response (PR) were 36.7 months (black 
line), which was significantly better than that of the patients with stable disease 
(SD)/progressive disease (PD)/ not evaluable (NE), i.e., 6.6 months  (gray line) (p <0.01). 
 
Supplementary Figure: Kaplan–Meier plot of overall survival since commencement of HAIC 
according to progression pattern. Patient prognosis did not differ among intra-hepatic growth 
(IHG) group (black line), new intra-hepatic lesion (NIH) group (gray line), and new 




Table 1. Patient characteristics 
 
  (n=27) 
Age, years   
 Median, Range 68, 44-84 
Gender, n (%)   
 Male 23 (85.2) 
ECOG PS a, n (%)   
 0 24 (88.9) 
 1 3 (11.1) 
HBs antigen b, n (%)   
 Positive 9 (33.3) 
HCV antibody c, n (%)   
 Positive 15 (55.6) 
Child-Pugh class at start of HAIC, n (%)   
 A 9 (33.3) 
 B 16 (59.3) 
 C* 2 (7.4) 
Child-Pugh class at start of sorafenib, n (%)   
 A 21 (77.8) 
 B** 6 (22.2) 
Ascites, n (%)   
 Presence 18 (66.7) 
Albumin, g/dL   
 Median, Range 3.2, 2.1-3.9 
Prothrombin consumption test, %   
 Median, Range 82, 37-112 
LCSGJ d tumor stage, n (%)   
 II, III 12 (44.4) 
 IVA 4 (14.8) 
 IVB 11 (40.7) 
Macroscopic vascular invasion, n (%)   
 Yes 7 (25.9) 
Extrahepatic spread, n (%)   
 Yes 12 (44.4) 
AFP e, ng/mL   
 Median, Range 404, <10-175560 
 
a. ECOG PS: Eastern Cooperative Oncology Group performance status 
b. HBs antigen: Hepatitis B surface antigen 
c. HCV antibody: Hepatitis C virus antibody 
d. LCSGJ: Liver Cancer Study Group of Japan 
e. AFP: α-fetoprotein 
*; Child-Pugh class B at decision making of HAIC 
**; Child-Pugh class A at decision making of sorafenib 
  
Table 2. HAIC toxicities 
    All grade Grade 3 Grade 4 
    n (%) n (%) n (%) 
Hematological toxicities       
  Leukocytopenia 20 (74.1) 10 (37.0) 0 (0) 
  Neutropenia 21 (77.8) 10 (37.0) 4 (14.8) 
  Anemia 12 (44.4) 1 (3.7) 1 (3.7) 
  Thrombocytopenia 22 (88.9) 13 (48.1) 0 (0) 
Nonhematological toxicities       
  Anorexia 7 (25.9) 0 (0) 0 (0) 
  Fever 5 (18.5) 0 (0) 0 (0) 
  Dirrhea 4 (14.8) 1 (3.7) 0 (0) 
  Fatigue 4 (14.8) 0 (0) 0 (0) 
  Hiccoughs 3 (11.1) 0 (0) 0 (0) 
  Gastric ulcer 3 (11.1) 0 (0) 0 (0) 
  Creatinine increased 2 (7.4) 0 (0) 0 (0) 
  Mucositis oral 2 (7.4) 0 (0) 0 (0) 
  Nausea 1 (3.7) 0 (0) 0 (0) 
  Ascites 1 (3.7) 0 (0) 0 (0) 
  Edema 1 (3.7) 0 (0) 0 (0) 
  Abdominal pain 1 (3.7) 0 (0) 0 (0) 
  Hypokalemia 1 (3.7) 0 (0) 0 (0) 
  Encephalopathy 1 (3.7) 0 (0) 0 (0) 
Device-related complications       
  Catheter obstruction 3 (11.1) 0 (0) 0 (0) 
  Hepatic artery occlusion 1 (3.7) 0 (0) 0 (0) 
  Vasculitis 1 (3.7) 0 (0) 0 (0) 





  Child-Pugh class*   Response to sorafenib   Progression pattern** 
  A B or C   PR SD PD NE   IHG g NIH h NEH i 
CR b 0 (0)   0 0   0 0 0 0   0 0 0 
PR c 8 (29.6)   1 7   0 4 3 1   3 0 1 
SD d 9 (33.3)   5 4   1 5 3 0   7 2 0 
PD e 9 (33.3)   3 6   0 4 4 1   6 2 0 
NE f 1 (3.7)   0 1   1 0 0 0   1 0 0 
Total 27 (100)   9 18   2 13 10 2   17 4 1 
 
 a. HAIC: hepatic arterial infusion chemotherapy 
 b. CR: complete response 
 c. PR: partial response 
 d. SD: stable disease 
 e. PD: progressive disease 
 f. NE: not evaluable 
 g. IHG: intra-hepatic growth 
 h. NIH: new intra-hepatic lesion 
 i. NEH: new extra-hepatic lesion 
*; at decision making of HAIC 
**; at termination of sorafenib therapy 
 
 Supplementary Table. Predictive marker for response to HAIC 




Age, years >=68 14 14.3 0.070 
  <68 13 46.2 
 
Gender Male 23 26.0 0.33 
  Female 4 50.0 
 
ECOG PS a 0 24 29.2 0.88 
  1 3 33.3 
 
HBs antigen b Positive 9 22.2 0.55 
  Negative 18 33.3 
 
HCV antibody c Positive 15 33.3 0.64 
  Negative 12 25.0 
 
Intrahepatic lesions, n >=5 17 29.4 0.97 
  <5 10 33.3 
 
Size of maximum lesion, mm >=40 14 35.7 0.47 
  <40 13 23.1 
 
Macroscopic vascular invasion Positive 8 12.5 0.30 
  Negative 20 35.0 
 
Extrahepatic spread Positive 12 33.3 0.71 
  Negative 15 26.7 
 
LCSGJ d tumor stage, n (%)  II, III 12 25.0 0.82 
   IVA 4 25.0 
 
   IVB 11 26.4 
 
Ascites Positive 18 33.3 0.55 
  Negative 9 22.2 
 
Albumin, g/dL >=3.5 9 22.2 0.55 
  <3.5 18 33.3 
 
Child-Pugh class A 9 11.1 0.14 
  B-C 18 38.9 
 
AFP e, ng/mL >=400 14 28.6 0.90 
  <400 13 30.8   
Progression pattern IHG f 17 17.6 0.068 
  NIH g 4 0.0   
  NEH h 1 100.0   
a. ECOG PS: Eastern Cooperative Oncology Group performance status 
b. HBs antigen: Hepatitis B surface antigen 
c. HCV antibody: Hepatitis C virus antibody 
d. LCSGJ: Liver Cancer Study Group of Japan 
e. AFP: α-fetoprotein 
f. IHG: intra-hepatic growth 
g. NIH: new intra-hepatic lesion 
h. NEH: new extra-hepatic lesion 
*; chi-squared test 
 
 
